Clinical Trial Update: Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of filgrastim, plerixafor, and sorafenib in FLT3-mutated acute myeloid leukemia; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Filgrastim (filgrastim)
• Plerixafor (Plerixafor)
• Sorafenib (Sorafenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myelogenous Leukemia, Leukemia | Phase 1 | Status: COMPLETED